TRxADE HEALTH Files Routine 8-K, Confirms Registration Details
Ticker: SCNX · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1382574
| Field | Detail |
|---|---|
| Company | Trxade Health, Inc (SCNX) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, regulatory-filing
TL;DR
**TRxADE HEALTH filed a routine 8-K, no major news.**
AI Summary
TRxADE HEALTH, INC. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing is a routine update to the SEC, primarily confirming the company's current registration details, including its incorporation in Delaware and its business address in Lutz, Florida. For investors, this filing is largely administrative and does not signal any immediate operational or financial changes, meaning it has a neutral impact on stock considerations.
Why It Matters
This filing is a standard administrative update, confirming basic company information with the SEC. It doesn't contain new financial or operational news, so it's unlikely to directly impact the stock price.
Risk Assessment
Risk Level: low — This 8-K is an administrative filing and does not disclose any new risks or material events that would impact the company's operations or financial standing.
Analyst Insight
Investors should view this as a routine administrative filing that provides no new material information for investment decisions. No immediate action is warranted based on this specific 8-K.
Key Players & Entities
- TRxADE HEALTH, INC. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for TRxADE HEALTH, INC.
- Lutz, Florida (company) — address of principal executive offices for TRxADE HEALTH, INC.
- January 16, 2024 (date) — date of earliest event reported in the 8-K
- January 17, 2024 (date) — date the 8-K was filed
FAQ
What is the purpose of this specific 8-K filing by TRxADE HEALTH, INC.?
This 8-K filing is a 'Current Report' under Section 13 or 15(D) of the Securities Exchange Act of 1934, reporting an 'Other Event' and 'Financial Statements and Exhibits'. It primarily serves to update or confirm administrative details with the SEC, such as the company's exact name, state of incorporation (Delaware), and principal executive offices (2420 Brunello Trace, Lutz, Florida 33558).
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 16, 2024.
What is the state of incorporation for TRxADE HEALTH, INC. as stated in the filing?
TRxADE HEALTH, INC. is incorporated in Delaware, as specified in the filing.
What is the business address listed for TRxADE HEALTH, INC. in this 8-K?
The business address listed for TRxADE HEALTH, INC. is 2420 Brunello Trace, Lutz, Florida 33558.
Does this 8-K filing indicate any changes in TRxADE HEALTH, INC.'s registered securities?
The filing lists 'Common Stock' as the 'Title of Each Class' of securities registered pursuant to Section 12(b) of the Act, but it does not indicate any changes to these registered securities; it merely confirms their status.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-17 09:05:13
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share MEDS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-002571.txt ( ) — 226KB
- meds-20240116.xsd (EX-101.SCH) — 3KB
- meds-20240116_lab.xml (EX-101.LAB) — 33KB
- meds-20240116_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRxADE HEALTH, INC. By: /s/ Suren Ajjarapu Name: Suren Ajjarapu Title: Chief Executive Officer Dated: January 17, 2024